Written by an experienced European Patent Attorney and scholar, this book sets out in
detail the framework for protection of pharmaceutical innovation under the SPC
Regulation. With a focus on both biotechnological innovation and secondary
innovation, and through extensive reference to the case law, Ulla Klinge surveys the
court’s evolving interpretation of legal and technical eligibility for this extended
term of protection. This book provides clear and pragmatic tools to reflect and
guide future practice, while offering key explanations and insights as to why and
how technological developments challenge the legal SPC framework.